2023 Multidisciplinary Thoracic Cancers Symposium onDemand
The 2023 Multidisciplinary Thoracic Cancers Symposium features case discussions; educational sessions on multidisciplinary therapies, new targeted therapies, immunotherapy, treatment and screening guidelines, supportive care; and oral abstract sessions highlighting the most current, evidence-based practices. The goal of this meeting is to provide participants with updates on current clinical and translational initiatives in thoracic malignancies, including targeted therapy, immunotherapy, advanced radiation techniques, surgical methodologies, and pathological advancements in molecular categorization that are relevant to daily clinical practice. Additionally, participants will be updated on the appropriate integration of these advancements in their daily practice, including indication, patient selection, combinations of different therapeutic modalities, prevention, and management of common toxicities in the context of potentially improved clinical outcomes. This educational activity focused on several of the most complex and controversial topics in the multidisciplinary management of patients with thoracic cancers to optimize incorporation of recent advances into daily practice.
This activity is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, physicists, nurses, diagnostic radiologists, pathologists, radiation therapists, radiation dosimetrists and pulmonologists.
Upon completion of this activity, participants should be able to do the following:
- Integrate locally ablative treatment modalities for appropriate patients with oligometastatic lung cancer.
- Identify the potential advantages of proton-beam radiation therapy for thoracic malignancies.
- Implement proper monitoring and intervention strategies for immune-related toxicities.
- Explain the benefit of CT screening for lung cancer.
- Discuss the relevance of molecular diagnostic testing in the management of patients with thoracic malignancies.
- Explain the role of multidisciplinary care for early-stage/locally advanced non-small cell lung cancer.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 17.75 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 17.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 17.75 Certificate of AttendanceThis activity was designated for 17.75 AMA PRA Category 1 Credit™.
ASTRO members must log in to the ASTRO website to view and receive the member rate.
Student/Grad Student/PGY: $349
Postdoctoral Fellow: $949
No refunds, extensions, or substitutions will be made for those registrants. Including those who for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.
The course and its materials will only be available on the ASTRO website for that 2 year period regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.”
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.